Latest Health It Market News

Nexsen Limited has initiated FDA engagement for its rapid Group B Streptococcus diagnostic sensor, aiming for expedited US market entry, while bolstering its leadership team and scientific credentials.

NTAW Holdings has secured an extension of its financial covenant waiver with Commonwealth Bank of Australia until March 2026, while continuing to reduce its borrowing facility.

Singular Health has submitted a 510(k) premarket notification to the FDA for its enhanced 3DICOM MD Cloud platform, aiming to expand imaging capabilities and introduce a scalable, cloud-native solution for medical image management.

RLF AgTech reports a robust 34% increase in Australian revenue for the four months to October 2025, driven by stronger distributor engagement and promising trial results. The company is poised for growth as it enters its critical January–June 2026 sales season with an expanded national footprint.

Resonance Health reports positive cash flow and significant progress in its clinical trials and Software-as-a-Medical Device business, setting the stage for growth in new international markets.

Medibank has set ambitious goals to triple its health segment earnings by FY30, expand its private health insurance market share, and double its health engagement, signaling a strategic pivot towards integrated, technology-driven care.

Salter Brothers Emerging Companies Limited has announced a further 12-month extension of its on-market share buy-back program, allowing the company to repurchase up to 8.45 million shares to maintain capital management flexibility and enhance shareholder value.

Hydrix Limited will have its trading suspension lifted on 13 October 2025 following the release of its audited financial statements for FY2025. Investors await clarity on the company’s financial health as it returns to the ASX.

EDU Holdings Limited is set to renew its on-market share buyback program, aiming to repurchase up to 14.4 million shares over the next year, continuing its strategy to enhance shareholder value.

TasFoods has agreed to sell its Pyengana Dairy business for $2 million, aiming to reduce debt and refocus on its poultry supply chain. The sale awaits shareholder approval with settlement expected by early November.

LTR Pharma has acquired a one-third equity stake in LevOmega Pty Ltd at no cost to shareholders, positioning itself in the growing pharmaceutical-grade omega-3 sector. This strategic move complements LTR’s existing intranasal pharmaceutical portfolio and aligns with its innovation-driven growth strategy.

Biome Australia has partnered with Green Cross Health to launch its Activated Probiotics across New Zealand’s largest pharmacy network, marking a pivotal step in its international growth strategy.